{"id":6521,"date":"2022-02-21T17:48:14","date_gmt":"2022-02-21T16:48:14","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=6521"},"modified":"2022-02-21T17:50:46","modified_gmt":"2022-02-21T16:50:46","slug":"autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/","title":{"rendered":"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\/c (Notice of Compliance with Conditions)"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h3 class=\"Default\">21\/02\/2022 \u2013\u00a0AB Science annonce aujourd&rsquo;hui avoir re\u00e7u l\u2019autorisation de l\u2019autorit\u00e9 de sant\u00e9 canadienne (Health Canada) pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique (SLA), sous le statut NOC\/c (Notice of Compliance with Conditions)<\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMi8wMi9IZWFsdGgtQ2FuYWRhLU5PQ2MtR3JhbnRlZC1WRlItVkYucGRmJnNldHRpbmdzPTExMTAxMTExMTExMTExMTExMDAmbGFuZz1lbi1VUw==#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-7183710ceafed85503b1c739a7b22462.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-7183710ceafed85503b1c739a7b22462 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2022\/02\/Health-Canada-NOCc-Granted-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1645460493469\" target=\"_blank\" id=\"default-btn-7183710ceafed85503b1c739a7b22462\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] 21\/02\/2022 \u2013\u00a0AB Science annonce aujourd&rsquo;hui avoir re\u00e7u l\u2019autorisation de l\u2019autorit\u00e9 de sant\u00e9 canadienne (Health Canada) pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique (SLA), sous le statut NOC\/c (Notice of Compliance with Conditions) [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[117,121,93,116],"class_list":["post-6521","post","type-post","status-publish","format-standard","hentry","category-2022-fr","tag-ab10015","tag-als-fr","tag-masitinib-fr","tag-riluzole","category-127","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\/c (Notice of Compliance with Conditions)<\/title>\n<meta name=\"description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\/c (Notice of Compliance with Conditions)\" \/>\n<meta property=\"og:description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-21T16:48:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-21T16:50:46+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\\\/c (Notice of Compliance with Conditions)\",\"datePublished\":\"2022-02-21T16:48:14+00:00\",\"dateModified\":\"2022-02-21T16:50:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\\\/\"},\"wordCount\":178,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"keywords\":[\"AB10015\",\"ALS\",\"Masitinib\",\"riluzole\"],\"articleSection\":[\"2022\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\\\/\",\"name\":\"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\\\/c (Notice of Compliance with Conditions)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-02-21T16:48:14+00:00\",\"dateModified\":\"2022-02-21T16:50:46+00:00\",\"description\":\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\\\/c (Notice of Compliance with Conditions)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\/c (Notice of Compliance with Conditions)","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/","og_locale":"fr_FR","og_type":"article","og_title":"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\/c (Notice of Compliance with Conditions)","og_description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","og_url":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/","og_site_name":"AB Science","article_published_time":"2022-02-21T16:48:14+00:00","article_modified_time":"2022-02-21T16:50:46+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\/c (Notice of Compliance with Conditions)","datePublished":"2022-02-21T16:48:14+00:00","dateModified":"2022-02-21T16:50:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/"},"wordCount":178,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"keywords":["AB10015","ALS","Masitinib","riluzole"],"articleSection":["2022"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/","url":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/","name":"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\/c (Notice of Compliance with Conditions)","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2022-02-21T16:48:14+00:00","dateModified":"2022-02-21T16:50:46+00:00","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/autorisation-de-health-canada-pour-soumettre-une-demande-de-mise-sur-le-marche-du-masitinib-dans-le-traitement-de-la-sla-sous-le-statut-noc-c-notice-of-compliance-with-conditions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Autorisation de Health Canada pour soumettre une demande de mise sur le march\u00e9 du masitinib dans le traitement de la SLA sous le statut NOC\/c (Notice of Compliance with Conditions)"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/6521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=6521"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/6521\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=6521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=6521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=6521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}